Form 4: Amgen SVP & CCO Exercises, Sells Stock Options

Amgen's Senior Vice President and Chief Compliance Officer, Nancy A. Grygiel, exercised and immediately sold stock options totaling 3,139 shares on November 20, 2025.

Summary

• Nancy A. Grygiel, Amgen Inc.'s Senior Vice President and Chief Compliance Officer, engaged in a series of stock transactions on November 20, 2025.
• Exercised non-qualified stock options (NQSO) to acquire 1,500 shares of common stock at an exercise price of $177.46 per share.
• Simultaneously sold 1,500 shares of common stock at an average price of $337.2625 per share, with prices ranging from $337.17 to $337.69.
• Exercised additional NQSO to acquire 1,639 shares of common stock at an exercise price of $162.6 per share.
• Simultaneously sold 1,639 shares of common stock at an average price of $337.2625 per share, with prices ranging from $337.17 to $337.69.
• Following these transactions, direct beneficial ownership stands at 7,225 shares, which includes 96 Dividend Equivalents (DEs) from unvested RSUs.
• Indirect beneficial ownership through the Company's 401(k) Plan is 104.6847 shares.

Sentiment

Score: 6

Explanation: The filing reports a routine exercise of stock options and subsequent sale of shares by a senior officer. While the sale itself doesn't add to direct equity exposure, the exercise of options indicates value realization by management. This is a common practice for executive compensation and tax planning.

Positives

• The executive realized significant gains by selling shares at an average price of $337.2625, substantially higher than the exercise prices of $177.46 and $162.6.
• The exercise of options, even if followed by an immediate sale, indicates that the options held value for the executive.

Negatives

• The immediate sale of all exercised shares by a senior officer, while common for tax and liquidity purposes, does not increase the officer's direct equity stake in the company.

Future Outlook

N/A

Industry Context

N/A

Stakeholder Impact

• Shareholders: The transactions are routine insider activity and are unlikely to have a significant direct impact on the company's share price or overall share structure.
• Management: The reporting person realized compensation value from the exercise and sale of stock options.

Key Dates

Recommendation

This Form 4 filing details a routine exercise and sale of stock options by a senior executive. Such transactions are common for executive compensation and tax planning, often pre-scheduled under Rule 10b5-1 plans. They do not typically signal a change in the company's fundamental outlook or warrant a change in investment recommendation based solely on this filing. The significant gain realized by the executive (sale price much higher than exercise price) is a positive for the executive but doesn't alter the investment thesis for the stock itself.

Keywords

Amgen, AMGN, Form 4, Insider Trading, Stock Options, Executive Compensation, Nancy Grygiel, SVP & CCO, Stock Sale, Option Exercise